Fondaparinux as an Anticoagulant in Haemofiltration in Patients With Acute Kidney Failure.

• Status: Terminated
• Trial end date: 2007-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this project is to assess the safety and effectiveness of fondaparinux, a new drug to prevent blood clotting in the continuous dialysis machine used in intensive care patients who have kidney failure.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Melbourne Health
• Treatments: Anticoagulants; Fondaparinux; PENTA

Criteria

Inclusion Criteria:

1. Adult patients (18 years or over) admitted to the ICU and expected to stay for more than 48 hours.

2. Patients who require continuous renal replacement therapy.

3. Patients who consent or if the patient is not competent, the next of kin who consent to inclusion in the study. .

-

Exclusion Criteria:

1. Patients aged less than 18 years of age.

2. Patients who are pregnant

3. Patients with a contraindication to anticoagulation for pre existing bleeding diathesis

4. Patients or next of kin who do not consent to study inclusion. -